These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 22149318)
1. Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials. Dagres N; Varounis C; Iliodromitis EK; Lekakis JP; Rallidis LS; Anastasiou-Nana M Am J Cardiovasc Drugs; 2011 Dec; 11(6):395-400. PubMed ID: 22149318 [TBL] [Abstract][Full Text] [Related]
2. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH; Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319 [TBL] [Abstract][Full Text] [Related]
3. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH; Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333 [TBL] [Abstract][Full Text] [Related]
4. Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Pisters R; Hohnloser SH; Connolly SJ; Torp-Pedersen C; Naditch-Brûlé L; Page RL; Crijns HJ; Europace; 2014 Feb; 16(2):174-81. PubMed ID: 24072451 [TBL] [Abstract][Full Text] [Related]
5. Impact of dronedarone in atrial fibrillation and flutter on stroke reduction. Christiansen CB; Torp-Pedersen C; Køber L Clin Interv Aging; 2010 Apr; 5():63-9. PubMed ID: 20396635 [TBL] [Abstract][Full Text] [Related]
6. Dronedarone for the treatment of atrial fibrillation and atrial flutter. Maund E; McKenna C; Sarowar M; Fox D; Stevenson M; Pepper C; Palmer S; Woolacott N Health Technol Assess; 2010 Oct; 14(Suppl. 2):55-62. PubMed ID: 21047492 [TBL] [Abstract][Full Text] [Related]
7. Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. Duray GZ; Schmitt J; Hohnloser SH J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):19S-23S. PubMed ID: 20472812 [TBL] [Abstract][Full Text] [Related]
8. Dronedarone: a promising alternative for the management of atrial fibrillation. Yalta K; Turgut OO; Yilmaz MB; Yilmaz A; Tandogan I Cardiovasc Drugs Ther; 2009 Oct; 23(5):385-93. PubMed ID: 19669399 [TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation of dronedarone in atrial fibrillation. De Ferrari GM; Dusi V Expert Opin Drug Saf; 2012 Nov; 11(6):1023-45. PubMed ID: 22971242 [TBL] [Abstract][Full Text] [Related]
10. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Naccarelli GV; Johnston SS; Lin J; Patel PP; Schulman KL Clin Cardiol; 2010 May; 33(5):270-9. PubMed ID: 20513065 [TBL] [Abstract][Full Text] [Related]
11. A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission. Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Gonzalez MD J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):24S-30S. PubMed ID: 21098416 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. Piccini JP; Hasselblad V; Peterson ED; Washam JB; Califf RM; Kong DF J Am Coll Cardiol; 2009 Sep; 54(12):1089-95. PubMed ID: 19744618 [TBL] [Abstract][Full Text] [Related]
13. Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial. Salam AM Expert Rev Cardiovasc Ther; 2012 Nov; 10(11):1345-9. PubMed ID: 23244355 [TBL] [Abstract][Full Text] [Related]
14. Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Torp-Pedersen C; Crijns HJ; Gaudin C; Page RL; Connolly SJ; Hohnloser SH; Europace; 2011 Aug; 13(8):1118-26. PubMed ID: 21576129 [TBL] [Abstract][Full Text] [Related]
15. A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers. Ezekowitz MD; Ellenbogen KA; DiMarco JP; Kaszala K; Boddy A; Geba GP; Koren A J Interv Card Electrophysiol; 2015 Mar; 42(2):69-76. PubMed ID: 25638303 [TBL] [Abstract][Full Text] [Related]
16. Dronedarone in patients with congestive heart failure: insights from ATHENA. Hohnloser SH; Crijns HJ; van Eickels M; Gaudin C; Page RL; Torp-Pedersen C; Connolly SJ; Eur Heart J; 2010 Jul; 31(14):1717-21. PubMed ID: 20436046 [TBL] [Abstract][Full Text] [Related]
17. Effects of dronedarone on all-cause mortality and on cardiovascular events in patients treated for atrial fibrillation: a meta-analysis of RCTs. De Vecchis R; Ariano C Minerva Cardioangiol; 2019 Apr; 67(2):163-171. PubMed ID: 30260141 [TBL] [Abstract][Full Text] [Related]
18. Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation. Duray GZ; Ehrlich JR; Hohnloser SH Curr Opin Cardiol; 2010 Jan; 25(1):53-8. PubMed ID: 19881340 [TBL] [Abstract][Full Text] [Related]
19. Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial. Blomström-Lundqvist C; Naccarelli GV; McKindley DS; Bigot G; Wieloch M; Hohnloser SH Europace; 2023 Mar; 25(3):845-854. PubMed ID: 36758013 [TBL] [Abstract][Full Text] [Related]